References
- Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its Eradication. WHO Geneva, Switzerland (1988).
- Moss B. Poxviridae: the viruses and their replication. In: Field’s Virology, 3rd edition. Lippincott-Raven, PA, USA (1996).
- Smith GL. Vaccinia virus immune evasion Immunol. Lett.65, 55–62 (1999).
- Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. Vaccinia virus immune evasion Immunol. Rev.159, 137–154 (1997).
- Haga IP, Bowie AG. Evasion of innate immunity by vaccinia virus. Parasitology130(Suppl.), S11–S25 (2005).
- Henderson DA, Borio LL, Lane JM. Smallpox and Vaccinia. In: Vaccines (4th edition). Plotkin, Orenstein (Eds). W.B. Saunders Company, NY, USA (2003).
- Kennedy JS, Frey SE, Yan L et al. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J. Infect. Dis.190,1286–1294 (2004).
- Demkowicz WE, Littawa RA, Wang J, Ennis FA. Human cytotoxic T-cell memory: long lived response to vaccinia virus. J. Virol.70(4), 2627–2631 (1996).
- Hammarlund E, Lewis MW, Hansen SG et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med.9, 1131–1137 (2003).
- Edgehill-Smith Y, Golding H, Manisschewitz J et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med.11, 740–747 (2005).
- Hopkins RH, Lane JM. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin. Infect. Dis.39, 819–826 (2004).
- Xu R, Johnson AJ, Liggett D, Bevan MJ. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol.172, 6265–6271 (2004).
- Buller RM, Palumbo GJ. Poxvirus pathogenesis. Microbiol. Rev.55, 80–122 (1991).
- Jing L, Chong TM, McClurkan CL, Huang J, Story BT, Koelle DM. Diversity in the acute CD8 T cell response to vaccinia virus in humans. J. Immunol.175, 7550–7559 (2005).
- Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination (vaccinia): a review, part II: adverse events.Clin. Infect. Dis.37(2), 251–271 2003).
- Fulginiti VA, Kempe CH, Hathaway WE et al. Progressive vaccinia in immunologically deficient individuals. New York: The National Foundation – March of Dimes, Birth Defects, Original Article Series, Immunologic Deficiency Diseases in Man.4, 129–145 (1968).
- Arness MK, Eckart RE, Love SS et al. Myopericarditis following smallpox vaccination. Am. J. Epidemiol.160, 642–651 (2004).
- Chen RT, Lane JM. Myocarditis: the unexpected return of smallpox vaccine adverse events. Lancet362, 1345–1346 (2003).
- Monath TP, Caldwell JR, Mundt W et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense. Internat. J. Infect. Dis.8(Suppl. 2), S31–S44 (2004).
- McCurdy LH, Larkin BD, Martin JE, Graham BS. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin. Infect. Dis.38, 1749–1753 (2004).
- Tartaglia J, Perkus ME, Taylor J et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology188, 217–232 (1992).
- Empig M, Merret-Gentil T, Dermody S et al. The attenuated vaccinia – lister vaccine LC16m8 protects rabbits from lethal rabbitpox challenge. National Foundation for Infectious Diseases 7th Annual Conference on Vaccine Research (May 2004).
- Moore Z, Seward JF, Lane JM. Smallpox. Lancet367, 425–435 (2006).
- Jahrling PB, Hensley LE, Martinez MJ et al. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl Acad. Sci. USA101, 15197–15204 (2004).